focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,385.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (0.215%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,385.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior to Host Capital Markets Day December 7

9 Nov 2022 08:30

RNS Number : 7168F
Indivior PLC
09 November 2022
 

 

 

Indivior to Host Capital Markets Day December 7, 2022 in New York City

Slough, UK, and Richmond, VA, November 9, 2022 - Indivior PLC (LON: INDV) today announced that it will be hosting a Capital Markets Day on Wednesday, December 7, 2022, in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team. The focus of the event will be detailing the company's strategic growth plans and roadmap for delivering long-term shareholder value.

 

The event will begin at 8:30 am EST and conclude at 12:30 pm EST. Due to seating capacity, in-person participation is limited to institutional investors and analysts.

 

For those wishing to attend in person, please RSVP to investorrelations@indivior.com and further location details will be provided. Remote participants will have the ability to ask questions.

 

Further details about the Capital Markets Day can be found at cmd.indivior.com.

 

To access the live webcast, please click INDV CMD 2022.

 

A webcast replay will be available after the event has concluded.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs approximately 1,000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEADFPESPAFFA
Date   Source Headline
14th Jun 20234:00 pmRNSHolding(s) in Company
13th Jun 20234:00 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSIndivior to Commence Trading on Nasdaq
7th Jun 20233:45 pmRNSHolding(s) in Company
2nd Jun 20235:17 pmRNSIndivior settles antitrust MDL with states and DC
1st Jun 20239:11 amRNSTotal Voting Rights
26th May 20234:20 pmRNSHolding(s) in Company
25th May 20232:30 pmRNSIndivior to Participate in Upcoming Conferences
24th May 20233:05 pmRNSHolding(s) in Company
23rd May 20236:05 pmRNSIndivior Files Form 20-F for US Listing
23rd May 20232:42 pmRNSHolding(s) in Company
23rd May 20238:30 amRNSHolding(s) in Company
23rd May 20237:00 amRNSUS FDA Approves OPVEE
12th May 20232:56 pmRNSHolding(s) in Company
10th May 20233:30 pmRNSDirector/PDMR Shareholding
10th May 202312:00 pmRNSBlock listing Interim Review
10th May 20238:51 amRNSHolding(s) in Company
4th May 20232:48 pmRNSResult of AGM
27th Apr 202312:00 pmRNS1st Quarter Results
25th Apr 20232:30 pmRNSIndivior to Participate in Conference
25th Apr 20239:26 amRNSHolding(s) in Company
20th Apr 20238:43 amRNSHolding(s) in Company
18th Apr 20238:09 amRNSHolding(s) in Company
17th Apr 20234:25 pmRNSHolding(s) in Company
11th Apr 20232:00 pmRNSNotice of Q1 Results
6th Apr 202312:24 pmRNSHolding(s) in Company
3rd Apr 20239:35 amRNSTotal Voting Rights
30th Mar 20232:37 pmRNSHolding(s) in Company
28th Mar 20233:21 pmRNSHolding(s) in Company
27th Mar 202311:42 amRNSAnnual Financial Report
24th Mar 20232:30 pmRNSDirector/PDMR Shareholding
23rd Mar 202310:02 amRNSBlock Listing of Shares
22nd Mar 20233:00 pmRNSDirector/PDMR Shareholding
16th Mar 20232:30 pmRNSDirector/PDMR Shareholding
15th Mar 20232:30 pmRNSDirector/PDMR Shareholding
13th Mar 20234:04 pmRNSDirector/PDMR Shareholding
13th Mar 20232:36 pmRNSHolding(s) in Company
8th Mar 20239:42 amRNSDirector/PDMR Shareholding
6th Mar 20234:00 pmRNSDirector/PDMR Shareholding
6th Mar 202310:21 amRNSHolding(s) in Company
2nd Mar 20231:56 pmRNSIndivior Completes Opiant Transaction
2nd Mar 20238:43 amRNSCompletion of Share Repurchase Program
1st Mar 20234:35 pmRNSDirector/PDMR Shareholding
1st Mar 202310:09 amRNSTotal Voting Rights
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20234:18 pmRNSHolding(s) in Company
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.